Facial pain adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,786 adverse event reports that record the MedDRA preferred term Facial pain. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 515 reports in the 12 months to June 2026 and 518 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 970 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 515 (under 0.1%) record this term. Reports for female patients were 70.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 91 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Facial pain name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		28
Actemra	Interleukin-6 receptor antagonist	40
Adapalene	Retinoid	37
Aimovig		28
Ambrisentan	Endothelin receptor antagonist	38
Amitriptyline		35
Ampyra	Potassium channel blocker	58
Apixaban	Factor Xa inhibitor	388
Aredia		61
Astrazeneca Covid-19 Vaccine		339
Atorvastatin		27
Aubagio	Pyrimidine synthesis inhibitor	42
Avonex	Interferon beta	93
Bisoprolol	beta-Adrenergic blocker	93
Bisoprolol fumarate	beta-Adrenergic blocker	303
Boniva		37
Botox	Acetylcholine release inhibitor	133
BOTOX Cosmetic	Acetylcholine release inhibitor	133
Candesartan	Angiotensin 2 receptor blocker	274
Candesartan cilexetil	Angiotensin 2 receptor blocker	163
Carbamazepine	Mood stabilizer	46
Cetirizine	Histamine-1 receptor antagonist	157
Cetirizine hydrochloride	Histamine-1 receptor antagonist	251
Ciprofloxacin	Fluoroquinolone antibacterial	30
Cosentyx	Interleukin-17A antagonist	51
Cymbalta		36
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	388
Diclofenac	Nonsteroidal anti-inflammatory drug	33
Digoxin	Cardiac glycoside	395
Dupixent	Interleukin-4 receptor alpha antagonist	257
Dysport	Acetylcholine release inhibitor	42
Eliquis	Factor Xa inhibitor	39
Enbrel	Tumor necrosis factor blocker	294
Esomeprazole	Proton pump inhibitor	294
Esomeprazole magnesium	Proton pump inhibitor	84
Felodipine	Dihydropyridine calcium channel blocker	383
Flonase	Corticosteroid	27
Fluorouracil	Nucleoside metabolic inhibitor	32
Forteo	Parathyroid hormone analog	68
Fosamax	Bisphosphonate	79
Gabapentin	Anti-epileptic agent	61
Gilenya	Sphingosine 1-phosphate receptor modulator	143
Human immunoglobulin g	Human immunoglobulin G	29
Humira		346
Hydrochlorothiazide	Thiazide diuretic	402
Imdur		359
Inflectra	Tumor necrosis factor blocker	35
Isosorbide dinitrate	Nitrate vasodilator	362
Isosorbide mononitrate	Nitrate vasodilator	373
Kesimpta	CD20-directed cytolytic antibody	30
Lansoprazole	Proton pump inhibitor	391
Levothyroxine		53
Levothyroxine sodium	l-Thyroxine	344
Linagliptin	Dipeptidyl peptidase 4 inhibitor	379
Lyrica		131
Methotrexate	Folate analog metabolic inhibitor	96
Metoclopramide	Dopamine-2 receptor antagonist	26
Metoprolol	beta-Adrenergic blocker	52
Naproxen	Nonsteroidal anti-inflammatory drug	380
Ocrevus	CD20-directed cytolytic antibody	57
Omalizumab	Anti-IgE	33
Omeprazole	Proton pump inhibitor	50
Opsumit	Endothelin receptor antagonist	33
Orencia	Selective T cell costimulation modulator	29
Oxervate		107
Prednisone	Corticosteroid	80
Pregabalin		65
Prolia	RANK ligand inhibitor	111
Ramipril	Angiotensin converting enzyme inhibitor	36
Rebif	Interferon beta	45
Remicade	Tumor necrosis factor blocker	31
Repatha	PCSK9 inhibitor	31
Revlimid	Thalidomide analog	41
Rinvoq	Janus kinase inhibitor	43
Rituximab	CD20-directed cytolytic antibody	30
Sandostatin LAR Depot		27
Simvastatin	HMG-CoA reductase inhibitor	371
Skyrizi	Interleukin-23 antagonist	30
Tecfidera		119
Tegretol	Mood stabilizer	77
Tramadol		39
Tymlos		30
Tysabri	Integrin receptor antagonist	157
Tyvaso	Prostacycline vasodilator	26
Uptravi	Prostacyclin receptor agonist	47
Xeljanz	Janus kinase inhibitor	88
Xolair	Anti-IgE	67
Xyrem	Central nervous system depressant	26
Zocor	HMG-CoA reductase inhibitor	40
Zoledronic acid	Bisphosphonate	30
Zometa		115

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 47 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Facial pain name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	318
Angiotensin 2 receptor blocker	481
Angiotensin converting enzyme inhibitor	73
Anti-epileptic agent	122
Anti-IgE	100
Atypical antipsychotic	59
beta-Adrenergic blocker	485
Bisphosphonate	160
Cardiac glycoside	395
CD20-directed cytolytic antibody	134
Corticosteroid	233
Dihydropyridine calcium channel blocker	391
Dipeptidyl peptidase 4 inhibitor	384
Endothelin receptor antagonist	99
Factor Xa inhibitor	438
Folate analog metabolic inhibitor	105
GLP-1 receptor agonist	60
Histamine-1 receptor antagonist	435
HMG-CoA reductase inhibitor	451
Human immunoglobulin G	55
Integrin receptor antagonist	169
Interferon beta	143
Interleukin-17A antagonist	53
Interleukin-4 receptor alpha antagonist	264
Interleukin-6 receptor antagonist	50
Janus kinase inhibitor	139
Kinase inhibitor	180
l-Thyroxine	353
Mood stabilizer	123
Nitrate vasodilator	741
Nonsteroidal anti-inflammatory drug	478
Nucleoside metabolic inhibitor	57
Opioid agonist	104
Parathyroid hormone analog	68
Potassium channel blocker	70
Prostacyclin receptor agonist	54
Prostacycline vasodilator	95
Proton pump inhibitor	864
Pyrimidine synthesis inhibitor	59
RANK ligand inhibitor	127
Retinoid	60
Serotonin reuptake inhibitor	66
Sodium-Glucose cotransporter 2 inhibitor	399
Sphingosine 1-phosphate receptor modulator	158
Thalidomide analog	56
Thiazide diuretic	402
Tumor necrosis factor blocker	409

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Facial pain, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Facial pain
Age	Reports	Share
Under 2	4	under 0.1%
2 to 11	61	0.7%
12 to 17	92	1%
18 to 44	1,428	16.3%
45 to 64	2,739	31.2%
65 to 74	987	11.2%
75 and over	733	8.3%
Age not given	2,742	31.2%

Sex of the patient in the reports that record Facial pain
Sex	Reports	Share
Female	6,221	70.8%
Male	1,924	21.9%
Unknown or not given	641	7.3%

Age and sex are as the report gives them. 67.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Facial pain: adverse event reports that record this term. https://reportedreactions.com/reaction/facial-pain/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Facial pain mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page